PCI The Journeys Within
CPHI 2026 – 23/07/2026

Current Edition

Current Features

Advertisement

Current features

Trust, Not Accuracy: Why Pharmacovigilance Teams Still Double-Check AI Output They Know to be Valid

AI output being correct doesn’t automatically equate to it being trusted. Some pharma companies that have been drawing on AI powered adverse event processing for a w...
Continue Reading →
Current features

Beyond One-Time RECIST 1.1 Training: Knowledge Acquisition and Retention

Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) provides standardised criteria for evaluating changes in tumour burden in solid-tumour clinica...
Continue Reading →
Current features

Beyond Familiar Sites: Rethinking Site Selection to Bridge Clinical Research and Routine Care

Despite the rise of decentralised trial models, clinical research delivery remains fundamentally dependent on sites. Yet the current U.S. site network is overburdene...
Continue Reading →
Current features

Advancing Precision Medicine in Oncology: Companion Diagnostic Devices and IRB Best Practices for Identification and Regulatory Assessment

Precision medicine has transformed the landscape of cancer treatment by shifting from histology-based to biomarker-driven therapies and enabling targeted interventio...
Continue Reading →
Current features

Renal Care in the USA Set for Change in 2026and Beyond Customised care options expand on results from pivotal trial and FDA clearance

Elevating Patient Care Around the world, individual physicians and healthcare providers strive to bring the highest standard of affordable care to their patient p...
Continue Reading →
Current features

Pharmacovigilance Under Pressure: Why the Workflows Surrounding Case Management Can No Longer Be Left to Chance

The pharmaceutical industry has made considerable investments in digital safety infrastructure over the past two decades and the results in individual case managemen...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026

Company Profiles